Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Authors :: John P. Leonard
Marek Trneny
Fritz Offner
Jiri Mayer
Huilai Zhang
Grzegorz S. Nowakowski
Phillip Scheinberg
Argyrios Gkasiamis
Joanna Mikita-Geoffroy
Everton Rowe
John G. Gribben
Source :: Blood. 140:561-563
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Full Text Access

Tools